All In Biotech

Drug Trial Radar · NCT02928224

Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Dec 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 702 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

702

Actual

Start

Oct 13, 2016

Primary completion

Feb 11, 2019

Study completion Nov 10, 2022

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany; Pierre Fabre Medicament; Ono Pharmaceutical Co., Ltd.
First posted
Oct 10, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib + cetuximab plus or minus binimetinib versus Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in patients with BRAFV600E mCRC whose disease has progressed after 1 or 2 prior regimens in the metastatic setting. The study contains a Safety Lead-in Phase in which the safety and tolerability of encorafenib + binimetinib + cetuximab will be assessed prior to the Phase 3 portion of the study.

Conditions

  • BRAF V600E-mutant Metastatic Colorectal Cancer

Interventions

  • EncorafenibDrug

    Orally, once daily.

  • BinimetinibDrug

    Orally, twice daily.

  • CetuximabDrug

    Standard of care.

  • IrinotecanDrug

    Standard of care.

  • Folinic AcidDrug

    Standard of care.

  • 5-FluorouracilDrug

    Standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. (Safety Lead-in) Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: Cycle 1 (up to 28 days)
  2. (Safety Lead-in) Number of Participants With Adverse Events (AEs)Time frame: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)
  3. (Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Interim AnalysisTime frame: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)
  4. (Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Final AnalysisTime frame: From start of study treatment until 30 days post last dose of study treatment (maximum treatment exposure of 280 weeks)
  5. (Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm - Interim AnalysisTime frame: From randomization to death due to any cause until 204 deaths were observed (maximum treatment exposure of 89.1 weeks for triplet arm and 52.4 weeks for control arm)
  6. (Phase 3) Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control ArmTime frame: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)

Locations

418 sites in 27 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • Mayo Clinic

    Phoenix, Arizona

  • Mayo Clinic

    Scottsdale, Arizona

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

    Duarte, California

  • Compassionate Care Research Group, Inc. at Compassionate Cancer Care Medical Group, Inc.

    Fountain Valley, California

  • Keck Hospital of USC - Norris Healthcare Center (HC3)

    Los Angeles, California

  • Keck Hospital of USC

    Los Angeles, California

  • LAC+USC Medical Center

    Los Angeles, California

  • Norris Healthcare Center 3 (HC3)

    Los Angeles, California

  • USC Eye Institute

    Los Angeles, California

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Harvard Eye Associates

    Orange, California

  • Rocky Mountain Lions Eye Institute

    Aurora, Colorado

  • University of Colorado Cancer Center - Anschutz Cancer Pavilion

    Aurora, Colorado

  • University of Colorado Denver CTO (CTRC)

    Aurora, Colorado

  • University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)

    Aurora, Colorado

  • University of Colorado Hospital Inpatient Pavillion'

    Aurora, Colorado

  • Smilow Cancer Hospital at Yale - New Haven

    New Haven, Connecticut

  • Temple Medical Center

    New Haven, Connecticut

  • Yale University, Yale Cancer Center

    New Haven, Connecticut

  • Smilow Cancer Hospital Care Center at North Haven

    North Haven, Connecticut

  • The Lennar Foundation Medical Center

    Coral Gables, Florida

  • Broward Health Medical Center

    Fort Lauderdale, Florida

  • Dr. Clayton Berger (opthalmology)

    Fort Lauderdale, Florida

  • Mehmet F. Hepgur, MD - Broward Health Medical Center

    Fort Lauderdale, Florida

  • Mayo Clinic Florida

    Jacksonville, Florida

  • Sylvester Comprehensive Cancer Center/UMHC

    Miami, Florida

  • Sylvester at Kendall

    Miami, Florida

  • Illinois CancerCare- Bloomington

    Bloomington, Illinois

  • University of Chicago Medical Center

    Chicago, Illinois

  • Illinois CancerCare- Galesburg

    Galesburg, Illinois

  • University of Chicago Comprehensive Cancer Center at Silver Cross Hospital

    New Lenox, Illinois

  • The University of Chicago Medicine Center for Advanced Care Orland Park

    Orland Park, Illinois

  • Illinois CancerCare- Ottawa

    Ottawa, Illinois

  • Illinois Cancer Care, PC

    Peoria, Illinois

  • Illinois Eye Center

    Peoria, Illinois

  • Carle Cancer Center

    Urbana, Illinois

  • Indiana University Health Hospital

    Indianapolis, Indiana

  • Indiana University Health Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana

Showing 40 of 418 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.